PANACEA (BIG 4-13)
PANACEA – anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer
A phase II trial evaluating the efficacy of MK-3475, an anti-PD-1 monoclonal antibody, and trastuzumab in patients with trastuzumab-resistant, HER2-positive metastatic breast cancers
What is 'PANACEA'?
'PANACEA' stands for: anti-PD-1 monoclonAl aNtibody in AdvanCed, trastuzumab-resistant, HER2-positive breAst cancer. This international clinical trial was designed for women diagnosed with advanced HER2 positive breast cancer.
What is the objective?
The PANACEA trial aims to determine the most suitable dose of KEYTRUDA (pembrolizumab, MK-3475) and trastuzumab when these drugs are used together and to assess if their combined use is an effective anti-cancer treatment.
Status: open for recruitment
Sherene Loi, MD, Department of Medical Oncology,Peter MacCallum Cancer Centre,East Melbourne, Victoria, Australia
Fabrice André, Prof., Department of Medical Oncology Institut Gustave Roussy,Villejuif,France
Coordinating research groups:
The global study is being led by the International Breast Cancer Study Group (IBCSG) under the (Breast International Group) BIG umbrella. In Australia, where the First Patient was included, the trial is coordinated by the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG).
Read the Press Release dated 28 april 2015: First patient included in Australia, where the study is being coordinated by the Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)
ClinicalTrials.gov Identifier: NCT02129556